AML-EV treatment increased Dickkopf-1 (DKK-1) expression and decreased osteogenesis of MSCs in an AML mouse model, providing direct evidence of the function of AML-EVs in vivo. This evidence concerns the gene DKK1 and acute myeloid leukemia.